Amphastar Pharmaceuticals Inc (AMPH)
NASDAQ:AMPH
Want to see AMPH full AI Analyst Report?
Earnings Data
Report Date
Aug 10, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.69Last Year’s EPS
0.85Same Quarter Last Year
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a mixed picture: operational and strategic positives (stable-to-growing total revenue, strong cash flow, successful new product launches, pipeline progress toward 2027, and active share repurchases) are offset by meaningful near-term headwinds (a 15% decline in BAQSIMI revenue driven by rebate/340B pressure, a 56% collapse in glucagon sales, rising costs and higher operating expenses, and materially lower net and adjusted earnings). Management has taken targeted actions (price increase, 340B validation, new product launch, continued R&D investment) to address the issues, but near-term margin and earnings pressure remain evident.Company Guidance
Net Revenues and Operational Cash Flow
Net revenues of $171.2 million in Q1 2026 versus $170.5 million in Q1 2025 (return to growth). Cash flow from operations of approximately $47.8 million during the quarter. Company maintains overall corporate sales guidance of mid-single-digit to high-single-digit unit growth for 2026.
BAQSIMI: Strong Unit Demand Despite Pricing Headwinds
BAQSIMI generated approximately $32.4 million in revenue and U.S. sales unit volumes increased ~8% year-over-year, indicating solid underlying demand. Management implemented a 3% list price increase effective May 1 and engaged an outside firm to address potential duplicate 340B rebate payments.
Primatene MIST Continued Momentum
Primatene MIST generated approximately $29.8 million in revenue, up ~2% year-over-year, with store-level sales increasing ~6.5% year-over-year driven by sustained consumer demand and commercial investment.
New Product Launches and Portfolio Expansion
Launched AMP-007 (ipratropium bromide inhalation) in April as the first and only generic inhaled ipratropium on the market, cited as the company’s top near-term growth driver. Other recently launched products helped grow other finished pharmaceutical product sales by 34% to $67.1 million (notable contributions: albuterol +$2.8M, teriparatide +$2.2M, iron sucrose +$1.4M).
Progress on Higher-Value Pipeline
Late-stage programs remain on track: insulin aspart biosimilar and GLP-1 ANDA planned for commercial launches in 2027. Continued advancement of early-stage proprietary assets (oncology, immunology) and plans for IND submissions; corticotropin program targeting Phase I in 2027.
Strong Balance Sheet and Capital Deployment
Company reports a strong financial position supporting R&D and selective M&A/licensing. Executed accelerated share repurchases of $29.5 million during the quarter (approximately 3% of share count), demonstrating capital return and confidence in the balance sheet.
AMPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AMPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $24.03 | $19.00 | -20.93% |
Feb 26, 2026 | $26.49 | $20.23 | -23.63% |
Nov 06, 2025 | $24.23 | $24.03 | -0.83% |
Aug 07, 2025 | $21.62 | $23.81 | +10.13% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Amphastar Pharmaceuticals Inc (AMPH) report earnings?
Amphastar Pharmaceuticals Inc (AMPH) is schdueled to report earning on Aug 10, 2026, After Close (Confirmed).
What is Amphastar Pharmaceuticals Inc (AMPH) earnings time?
Amphastar Pharmaceuticals Inc (AMPH) earnings time is at Aug 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMPH EPS forecast?
AMPH EPS forecast for the fiscal quarter 2026 (Q2) is 0.69.